Published in final edited form as:

Biochem Biophys Res Commun. 2013 May 10; 434(3): 566–571. doi:10.1016/j.bbrc.2013.03.115.

Adenosine A_{2A} receptor-dependent proliferation of pulmonary endothelial cells is mediated through calcium mobilization, PI3-kinase and ERK1/2 pathways

Aftab Ahmad^{1,*}, Jerome B. Schaack², Carl W. White¹, and Shama Ahmad¹

¹Pediatric Airway Research Center, Department of Pediatrics, University of Colorado, Denver, Aurora CO

²Department of Microbiology, University of Colorado, Denver, Aurora CO

Abstract

Hypoxia and HIF-2 α -dependent A_{2A} receptor expression and activation increase proliferation of human lung microvascular endothelial cells (HLMVECs). This study was undertaken to investigate the signaling mechanisms that mediate the proliferative effects of A_{2A} receptor. A_{2A} receptor-mediated proliferation of HLMVECs was inhibited by intracellular calcium chelation, and by specific inhibitors of ERK1/2 and PI3-kinase (PI3K). The adenosine A_{2A} receptor agonist CGS21680 caused intracellular calcium mobilization in controls and, to a greater extent, in A_{2A} receptor-overexpressing HLMVECs. Adenoviral-mediated A_{2A} receptor overexpression as well as receptor activation by CGS21680 caused increased PI3K activity and Akt phosphorylation. Cells overexpressing A_{2A} receptor also manifested enhanced ERK1/2 phosphorylation upon CGS21680 treatment. A_{2A} receptor activation also caused enhanced cAMP production. Likewise, treatment with 8Br-cAMP increased PI3K activity. Hence A_{2A} receptor-mediated cAMP production and PI3K and Akt phosphorylation are potential mediators of the A_{2A}-mediated proliferative response of HLMVECs. Cytosolic calcium mobilization and ERK1/2 phosphorylation are other critical effectors of HLMVEC proliferation and growth. These studies underscore the importance of adenosine A_{2A} receptor in activation of survival and proliferative pathways in pulmonary endothelial cells that are mediated through PI3K/Akt and ERK1/2 pathways.

Keywords

adenosine; A_{2A} receptor; microvascular endothelial cells; pulmonary; intracellular calcium; PI3K; ERK1/2

© 2013 Elsevier Inc. All rights reserved.

*Corresponding Author: Aftab Ahmad Ph.D, Pediatric Airway Research Center, Department of Pediatrics, P15-4016, Mailstop 8615, University of Colorado, Denver, Aurora, CO 80045, Ph. No 303-724-7339, Fax No.303-724-7334, Aftab.Ahmad@UCDenver.edu.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Introduction

Hypoxia may occur locally, regionally, or systemically in various lung diseases or in association with ischemic injury, causing activation of adaptive pathways. Hypoxia also increases intracellular and extracellular adenosine [1]. Several studies, including our own, have shown that adenosine and its analogs can promote endothelial cell proliferation and migration [2,3,4,5,6,7,8]. Hypoxic proliferation of endothelial cells is important in disease processes including pulmonary hypertension where the proliferative phenotype can result in vascular remodeling and subsequent narrowing of the blood vessel lumen. Factors that lead to vascular remodeling are incompletely understood, but likely the causes are multifactorial.

The biological activity of adenosine is mediated mainly through its binding to four receptors, namely A₁, A_{2A}, A_{2B} and A₃[9]. These appear to have distinct function(s) in specific cell types. While A₁ and A₃ receptors inhibit adenylate cyclase activity, A_{2A} and A_{2B} stimulate it. Further, A₁ and A_{2A} have higher affinities for adenosine relative to A_{2B} and A₃. Therefore, depending on cell type, adenosine levels and adenosine receptor subtypes present, adenosine can differentially influence cell function and phenotype.

Extracellular adenosine, through its receptors, can modulate several signaling pathways including the PI3-kinase/Akt pathway and the MAPK pathways [10,11]. Depending on cell type, activation of A_{2A} receptor can either increase or decrease ERK1/2 phosphorylation [12,13,14,15]. Similarly activation of adenosine receptors can also increase or decrease PI3-kinase (PI3K) activity [16,17,18]. PI3K and Akt also can be involved in mediating protective effects of adenosine A_{2A} receptor against ischemia-reperfusion injury in heart and liver [16,19,20]. Further, A_{2A} receptor activation can normalize altered cell cycle signaling and promotes wound healing in diseased mice [21].

We have shown previously that hypoxia increases adenosine A_{2A} receptor expression by a HIF-2 α -dependent pathway in pulmonary endothelial cells [8]. In addition, we found that adenosine A_{2A} receptor increases proliferation of pulmonary endothelial cells [8]. In the current report, we used primary cultures of human lung microvascular endothelial cells to determine mechanism(s) by which adenosine A_{2A} receptor causes proliferation.

Materials and Methods

Cell Culture

HLMVECs were cultured in endothelial cell basal medium (EBM-2) supplemented with VEGF, human FGF, human EGF, hydrocortisone, ascorbic acid, insulin-like growth factor-1, GA-1000 (gentamicin/amphotericin-B), and 5% FBS per the supplier's protocol (Lonza).

Adenoviral transduction

Adenoviral A_{2A} (Ad.A_{2A}) was generated following the protocols outlined before [8]. Adenoviral transductions of HLMVECs were carried out at a multiplicity of infection of 10 plaque forming units per cell. For transduction controls Ad.LacZ was used.

RNA Isolation and RTPCR

For assessing mRNA levels, total RNA was isolated from cells, cDNA was synthesized and RTPCR was carried out with gene specific primers and Taqman probes as described by us previously (1).

Cell proliferation assay

HLMVECs were seeded on 6-well plates at a density of 1.3×10^5 cells per well in EBM2 complete medium. Medium was replaced with 1% FBS-containing medium 24h later. Next day the cells were transduced with Ad.LacZ or Ad.A_{2A} in 2% FBS-containing medium. Twenty four hours post transduction diluent or inhibitors were added and incubated for an additional 24 hr after which cells were trypsinized and counted using a Bio Rad automated cell counter.

Calcium Assay

A_{2A}- or ATP (positive control)-induced intracellular calcium mobilization was measured using a fluorescence technique as described previously [22]. Cells cultured on 96-well microtiter plates were loaded with 5 μ M no wash (NW) Fluo-4-AM (Molecular Probes) dye for 90 min. Subsequent steps were performed with a Fluorometric Imaging Plate Reader (FLIPR; Molecular Devices). Test compounds were added, and cells were monitored for 20 min to detect agonist activity. Net peak calcium, expressed in arbitrary fluorescence units, was measured.

Western blot analysis of cellular extracts for phospho-ERK1/2 and phospho-Akt

Western blots were carried out as described in detail before [23]. Briefly, 20 μ g of total protein lysate were subjected to SDS-PAGE (4–15%) and the separated proteins were transferred to nitrocellulose membranes using standard procedure. Phospho-ERK1/2 (Tyr 202/Thr 204) and phosphorylated Akt (Ser473) were detected using polyclonal antibodies (Cell Signaling Technology, Danvers, MA). Blots were probed with horseradish-peroxidase conjugated anti-rabbit antibody. Immunoreactive bands were detected using an enhanced chemiluminescence detection reagent (Pierce, Rockford, IL) followed by exposure to Hyperfilm (Amersham Pharmacia Biotech Inc.). For detection of the non-phosphorylated forms of ERK1/2 and Akt, respective membranes were stripped of the bound antibodies, blocked with 5% nonfat dry milk in TBS-T, and reprobed with rabbit polyclonal antibodies against total ERK1/2 and Akt (Cell Signaling Technology, Danvers, MA).

Measurement of intracellular cAMP levels

Using confluent HLMVECs in 24-well plates, cAMP levels were determined under basal conditions and in cells challenged for 10 min with CGS21680 (1 μ M). After treatment cells were washed with HBSS containing PMSF and sodium orthovanadate and then scrapped in the same buffer and pelleted. Cells pellets were resuspended in 0.1 N HCl for 10 min after which the contents were centrifuged and the supernatant collected for cAMP assay using ELISA (ELISA Tech, Denver, CO).

Assay for PI3-kinase Activity

PI3-kinase assay was carried out as described by us before [24]. PI3K activity was assessed by the incorporation of [32 P]ATP into exogenous phosphoinositide resulting in the production of PI3-phosphate (PI3-P). HLMVEC were lysed in buffer (20 mM Tris-HCl, pH 7.5, containing 137 mM NaCl, 1 mM CaCl₂, 1 mM MgCl₂, 0.2 mM Na₃VO₄, protease inhibitor cocktail (Calbiochem, La Jolla, CA), 1 mM PMSF, 10 mM sodium fluoride, 1% NP-40, and 1 mM EDTA) after treatments and the PI3K enzyme immunoprecipitated with anti-phospho-Tyr agarose conjugate or anti-p85 agarose conjugate. The enzyme was then incubated with phosphatidylinositol and [32 P]ATP in kinase buffer for 15 min at 37°C. The reaction was terminated by the addition of 1 M HCl, and lipids were then extracted using a mixture of chloroform and methanol (1:1). The lower chloroform phase containing the resulting PI3-P was separated by TLC and visualized by autoradiography. The product was identified by comparing its relative mobility value with the relative mobility value of the standard PI3-P, which was visualized by exposure of TLC plates to phospholipid-specific molybdenum blue spray reagent.

Statistical Analysis

All statistical analyses were performed with JMP software (SAS Institute, Cary, NC). Means were compared by two-tailed t test for comparison between two groups and one-way ANOVA followed by the Tukey-Kramer test for multiple comparisons. A P value of < 0.05 was considered significant.

Results

Adenosine A_{2A} receptor-dependent proliferation of HLMVECs is mediated by intracellular calcium mobilization and cell survival kinases

Hypoxia and HIF-2 have been shown to increase endothelial proliferation along with increase in A_{2A} receptor expression [8,25]. A_{2A} receptor overexpression and activation in HLMVECs causes enhanced proliferation, increased migration and angiogenesis [8]. Since kinases such as PI3K and ERK1/2 along with intracellular calcium mobilization play critical roles in promoting endothelial cell growth [26,27,28], and A_{2A} receptor has been implicated in activating these kinases in some cell types [11,16,19], we reasoned that these could be involved in A_{2A} receptor-mediated proliferation. To investigate the downstream pathways involved in A_{2A}-dependent proliferation, HLMVECs were transduced with Ad.LacZ or Ad.A_{2A} and treated with inhibitors of PI3K, ERK1/2 and intracellular calcium chelator BAPTA prior to assessing proliferation. As expected, A_{2A} overexpression increased proliferation by HLMVECs (Figure 1). We used the specific A_{2A} receptor antagonist SCH442416 to determine that the increased proliferation was indeed due to A_{2A} receptor. A_{2A} receptor-mediated proliferation in HLMVEC was attenuated by inhibition of ERK1/2, PI3K or by intracellular calcium inhibition (Figure 1A & 1B).

Adenosine A_{2A} receptor activity mediates cellular calcium signaling response

Intracellular calcium ([Ca²⁺]_i) mobilization plays an important role in pulmonary endothelial function [28,29]. Many endothelial cell primary messengers, such as ATP, activate specific

receptors and increase $[Ca^{2+}]_i$ [28,29]. We evaluated whether A_{2A} receptor overexpression and activation by its specific agonist CGS21680 could mobilize $[Ca^{2+}]_i$ in HLMVECs. A_{2A} receptor activation increased $[Ca^{2+}]_i$ in HLMVECs similar to that due to extracellular ATP (Figure 2) in control, Ad.LacZ- or Ad. A_{2A} -overexpressing HLMVECs. The magnitude of calcium mobilization appeared greater in Ad. A_{2A} -expressing cells. In these cells, however, basal cytosolic calcium levels were lower than those seen in control or Ad.LacZ-expressing cells (Figure 2).

Protein tyrosine kinases mediate adenosine A_{2A} receptor-dependent PI3K and Akt activation

Protein tyrosine kinases are important for downstream signaling to effect PI3K and Akt activation in endothelial cells [30,31]. Adenosine is a natural ligand for adenosine receptors. We therefore investigated PI3K activity upon treatment of HLMVECs with adenosine or its stable analog, 2-chloro-adenosine. Both adenosine and 2-chloro-adenosine caused increased PI3K activity (Figure 3A). Treatment with the specific A_{2A} receptor agonist CGS21680 also enhanced PI3K phosphorylation in HLMVECs (Figure 3B). Adenosine and A_{2A} receptor agonist CGS21680 also increased Akt phosphorylation (Figure 3C and 3D). Some studies have shown that adenosine A_{2A} receptor activates protein tyrosine kinases [32,33]. Therefore, we assessed the effect of genistein, a protein tyrosine kinase inhibitor, on Akt phosphorylation. Genistein inhibited adenosine A_{2A} receptor-induced Akt phosphorylation (Figure 3E).

Adenosine A_{2A} receptor activation enhances cAMP production

The cellular effects of A_{2A} receptor activation are mediated by adenylate cyclase activation and cAMP production in endothelial cells [34]. Treatment of HLMVECs with A_{2A} receptor agonist CGS21680 increased cAMP (Figure 3F). To understand whether A_{2A} receptor-mediated cAMP production caused PI3K activation, we treated HLMVECs with 8-Br-cAMP, a stable analog of cAMP. Treatment of HLMVECs with 8-Br-cAMP enhanced PI3K activity (Figure 3G).

Adenosine A_{2A} receptor activation and overexpression promote ERK1/2 phosphorylation

ERK1/2 phosphorylation mediates hypoxia-induced proliferation in endothelial cells [35]. We sought to determine whether ERK1/2 contributed to proliferative effects of A_{2A} receptor activation. Treatment of HLMVEC with CGS21680 increased ERK1/2 phosphorylation within 5 minutes (Figure 4A). This effect was transient and diminished at later time points. Similarly, CGS21680 treatment of cells overexpressing A_{2A} receptor also resulted in robust ERK1/2 phosphorylation (Figure 4B).

Discussion

Among adenosine receptor subtypes in pulmonary endothelial cells, A_{2A} has a characteristic role in that it is induced by hypoxia and HIF-2 α and it can promote endothelial proliferation [8]. This is in sharp contrast to its function in other cell types, including PC12 (pheochromocytoma) and smooth muscle cells, where adenosine A_{2A} receptor activation decreased proliferation, and receptor knockout caused increased proliferation [36,37,38].

Thus, the role of this receptor is dependent on cell and tissue type. ERK1/2 and PI3K are known mediators of growth and proliferation, and several studies suggest that these could have a role in A_{2A} receptor-mediated signaling. Endothelial dysfunction, as seen in pulmonary hypertension, can cause PI3K/Akt and ERK1/2 pathway activation [39,40,41]. However, mechanisms of such activation are unclear. It appears that activation of A_{2A} receptor in HLMVECs can cause activation of the pro-proliferative PI3K/Akt and ERK1/2 pathways as inhibition of both ERK1/2 and PI3K can diminish the proliferative response to A_{2A} receptor activation.

Adenosine is a natural ligand for adenosine receptors and adenosine synthesis is induced by hypoxia [42]. Adenosine-activated signaling pathways are incompletely understood in pulmonary vascular cells. This point is relevant since significant differences exist in endothelial cells arising from different vascular beds [43,44,45]. Adenosine caused increased Akt phosphorylation as well as increased PI3K activity, possibly through A_{2A} receptor activation. The effect was mimicked by CGS21680, the specific agonist of A_{2A} receptor, and also by cAMP, which is formed upon activation of the receptor. These findings are consistent with another report in which A_{2A} receptor activated PI3K in hepatocytes through a cAMP/adenylyl cyclase-dependent pathway [46].

Adenosine A_{2A} receptor is also known to couple to tyrosine kinases [33,47], and tyrosine kinase inhibitors could influence PI3K/Akt signaling. Genistein, a tyrosine kinase inhibitor and inhibitor of PI3K/Akt [48], caused decreased A_{2A} receptor-mediated Akt phosphorylation. The fact that genistein can also reverse pulmonary hypertension [49] further highlights the significance of A_{2A} receptor in such diseases where endothelial proliferation is a hallmark. Additionally, the fact that A_{2A} receptor activation also increases ERK1/2 phosphorylation further supports its pro-proliferative role.

These studies underscore the importance of adenosine A_{2A} receptor in activation of survival and proliferative pathways in pulmonary endothelial cells. Additionally, these studies suggest that A_{2A} receptor could be targeted to decrease vascular remodeling in diseases such as pulmonary hypertension wherein endothelial cell proliferation is excessive.

Acknowledgments

This work was supported by a Scientist Development Grant from the American Heart Association 0830418N (AA), NIH K12 award KL2RR025779 (SA), NIH P50 HL084923 (SCCOR: CWW) and NIH U54 ES015678 (CWW).

References

1. Ahmad, A.; White, CW.; Ahmad, S. Hypoxia-Inducible Factors and Adenosine Signaling in Vascular Growth. In: Gerasimovskaya, E.; Kaczmarek, E., editors. Extracellular ATP and Adenosine as Regulators of Endothelial Cell Function. Springer; Netherlands: 2010. p. 113-124.
2. Dubey RK, Gillespie DG, Jackson EK. A(2B) adenosine receptors stimulate growth of porcine and rat arterial endothelial cells. Hypertension. 2002; 39:530–535. [PubMed: 11882603]
3. Ethier MF, Chander V, Dobson JG Jr. Adenosine stimulates proliferation of human endothelial cells in culture. Am J Physiol. 1993; 265:H131–138. [PubMed: 8342624]
4. Ethier MF, Dobson JG Jr. Adenosine stimulation of DNA synthesis in human endothelial cells. Am J Physiol. 1997; 272:H1470–1479. [PubMed: 9087626]

5. Grant MB, Davis MI, Caballero S, Feoktistov I, Biaggioni I, Belardinelli L. Proliferation, migration, and ERK activation in human retinal endothelial cells through A(2B) adenosine receptor stimulation. *Invest Ophthalmol Vis Sci.* 2001; 42:2068–2073. [PubMed: 11481274]
6. Luty GA, Mathews MK, Merges C, McLeod DS. Adenosine stimulates canine retinal microvascular endothelial cell migration and tube formation. *Curr Eye Res.* 1998; 17:594–607. [PubMed: 9663849]
7. Meininger CJ, Schelling ME, Granger HJ. Adenosine and hypoxia stimulate proliferation and migration of endothelial cells. *Am J Physiol.* 1988; 255:H554–562. [PubMed: 3414822]
8. Ahmad A, Ahmad S, Glover L, Miller SM, Shannon JM, Guo X, Franklin WA, Bridges JP, Schaack JB, Colgan SP, White CW. Adenosine A2A receptor is a unique angiogenic target of HIF-2 α in pulmonary endothelial cells. *Proc Natl Acad Sci U S A.* 2009; 106:10684–10689. [PubMed: 19541651]
9. Muller CE, Scior T. Adenosine receptors and their modulators. *Pharm Acta Helv.* 1993; 68:77–111. [PubMed: 8234392]
10. McIntosh VJ, Lasley RD. Adenosine receptor-mediated cardioprotection: are all 4 subtypes required or redundant? *J Cardiovasc Pharmacol Ther.* 2012; 17:21–33. [PubMed: 21335481]
11. Schulte G, Fredholm BB. Signalling from adenosine receptors to mitogen-activated protein kinases. *Cell Signal.* 2003; 15:813–827. [PubMed: 12834807]
12. Germack R, Dickenson JM. Characterization of ERK1/2 signalling pathways induced by adenosine receptor subtypes in newborn rat cardiomyocytes. *Br J Pharmacol.* 2004; 141:329–339. [PubMed: 14751870]
13. Ribe D, Sawbridge D, Thakur S, Hussey M, Ledent C, Kitchen I, Hourani S, Li JM. Adenosine A2A receptor signaling regulation of cardiac NADPH oxidase activity. *Free Radic Biol Med.* 2008; 44:1433–1442. [PubMed: 18206127]
14. Save S, Persson K. Effects of adenosine A(2A) and A(2B) receptor activation on signaling pathways and cytokine production in human uroepithelial cells. *Pharmacology.* 2010; 86:129–137. [PubMed: 20689344]
15. Zhang L, Paine C, Dip R. Selective regulation of nuclear orphan receptors 4A by adenosine receptor subtypes in human mast cells. *J Cell Commun Signal.* 2010; 4:173–183. [PubMed: 21234122]
16. Boucher M, Pesant S, Falcao S, de Montigny C, Schampaert E, Cardinal R, Rousseau G. Post-ischemic cardioprotection by A2A adenosine receptors: dependent of phosphatidylinositol 3-kinase pathway. *J Cardiovasc Pharmacol.* 2004; 43:416–422. [PubMed: 15076226]
17. Villarreal F, Epperson SA, Ramirez-Sanchez I, Yamazaki KG, Brunton LL. Regulation of cardiac fibroblast collagen synthesis by adenosine: roles for Epac and PI3K. *Am J Physiol Cell Physiol.* 2009; 296:C1178–1184. [PubMed: 19279233]
18. Ochaion A, Bar-Yehuda S, Cohen S, Amital H, Jacobson KA, Joshi BV, Gao ZG, Barer F, Patoka R, Del Valle L, Perez-Liz G, Fishman P. The A3 adenosine receptor agonist CF502 inhibits the PI3K, PKB/Akt and NF-kappaB signaling pathway in synoviocytes from rheumatoid arthritis patients and in adjuvant-induced arthritis rats. *Biochem Pharmacol.* 2008; 76:482–494. [PubMed: 18602896]
19. Dal Ponte C, Alchera E, Follenzi A, Imarisio C, Prat M, Albano E, Carini R. Pharmacological postconditioning protects against hepatic ischemia/reperfusion injury. *Liver Transpl.* 2011; 17:474–482. [PubMed: 21445931]
20. Solenkova NV, Solodushko V, Cohen MV, Downey JM. Endogenous adenosine protects preconditioned heart during early minutes of reperfusion by activating Akt. *Am J Physiol Heart Circ Physiol.* 2006; 290:H441–449. [PubMed: 16155103]
21. Altavilla D, Squadrito F, Polito F, Irrera N, Calo M, Lo Cascio P, Galeano M, La Cava L, Minutoli L, Marini H, Bitto A. Activation of adenosine A2A receptors restores the altered cell-cycle machinery during impaired wound healing in genetically diabetic mice. *Surgery.* 2011; 149:253–261. [PubMed: 20570301]
22. Ahmad S, Ahmad A, Rancourt RC, Neeves KB, Loader JE, Hendry-Hofer T, Di Paola J, Reynolds SD, White CW. Tissue factor signals airway epithelial basal cell survival via coagulation and

- protease-activated receptor isoforms 1 and 2. *Am J Respir Cell Mol Biol*. 2013; 48:94–104. [PubMed: 23065128]
23. Ahmad S, Ahmad A, McConville G, Schneider BK, Allen CB, Manzer R, Mason RJ, White CW. Lung epithelial cells release ATP during ozone exposure: signaling for cell survival. *Free Radic Biol Med*. 2005; 39:213–226. [PubMed: 15964513]
 24. Ahmad S, Ahmad A, Gerasimovskaya E, Stenmark KR, Allen CB, White CW. Hypoxia protects human lung microvascular endothelial and epithelial-like cells against oxygen toxicity: role of phosphatidylinositol 3-kinase. *Am J Respir Cell Mol Biol*. 2003; 28:179–187. [PubMed: 12540485]
 25. Ahmad A, Ahmad S, Malcolm KC, Miller S, Hendry-Hofer T, Schaack JB, White CW. Differential Regulation of Pulmonary Vascular Cell Growth by HIF-1 α and HIF-2 α . *Am J Respir Cell Mol Biol*. 2013
 26. Woodward HN, Anwar A, Riddle S, Taraseviciene-Stewart L, Fragoso M, Stenmark KR, Gerasimovskaya EV. PI3K, Rho, and ROCK play a key role in hypoxia-induced ATP release and ATP-stimulated angiogenic responses in pulmonary artery vasa vasorum endothelial cells. *Am J Physiol Lung Cell Mol Physiol*. 2009; 297:L954–964. [PubMed: 19684203]
 27. Montiel M, de la Blanca EP, Jimenez E. P2Y receptors activate MAPK/ERK through a pathway involving PI3K/PDK1/PKC-zeta in human vein endothelial cells. *Cell Physiol Biochem*. 2006; 18:123–134. [PubMed: 16914897]
 28. Ahmad S, Ahmad A, White CW. Purinergic signaling and kinase activation for survival in pulmonary oxidative stress and disease. *Free Radic Biol Med*. 2006; 41:29–40. [PubMed: 16781450]
 29. Moore TM, Chetham PM, Kelly JJ, Stevens T. Signal transduction and regulation of lung endothelial cell permeability. Interaction between calcium and cAMP. *Am J Physiol*. 1998; 275:L203–222.
 30. Shen J, Halenda SP, Sturek M, Wilden PA. Cell-signaling evidence for adenosine stimulation of coronary smooth muscle proliferation via the A1 adenosine receptor. *Circ Res*. 2005; 97:574–582. [PubMed: 16100051]
 31. Hong BZ, Park SA, Kim HN, Ma TZ, Kim HG, Kang HS, Kim HG, Kwak YG. Basic fibroblast growth factor increases intracellular magnesium concentration through the specific signaling pathways. *Mol Cells*. 2009; 28:13–17. [PubMed: 19711039]
 32. Lee FS, Chao MV. Activation of Trk neurotrophin receptors in the absence of neurotrophins. *Proc Natl Acad Sci U S A*. 2001; 98:3555–3560. [PubMed: 11248116]
 33. Wiese S, Jablonka S, Holtmann B, Orel N, Rajagopal R, Chao MV, Sendtner M. Adenosine receptor A2A-R contributes to motoneuron survival by transactivating the tyrosine kinase receptor TrkB. *Proc Natl Acad Sci U S A*. 2007; 104:17210–17215. [PubMed: 17940030]
 34. Ray CJ, Marshall JM. The cellular mechanisms by which adenosine evokes release of nitric oxide from rat aortic endothelium. *J Physiol*. 2006; 570:85–96. [PubMed: 16239264]
 35. Schafer M, Schafer C, Ewald N, Piper HM, Noll T. Role of redox signaling in the autonomous proliferative response of endothelial cells to hypoxia. *Circ Res*. 2003; 92:1010–1015. [PubMed: 12690038]
 36. Dubey RK, Gillespie DG, Osaka K, Suzuki F, Jackson EK. Adenosine inhibits growth of rat aortic smooth muscle cells. Possible role of A2b receptor. *Hypertension*. 1996; 27:786–793. [PubMed: 8613241]
 37. Sun CN, Cheng HC, Chou JL, Lee SY, Lin YW, Lai HL, Chen HM, Chern Y. Rescue of p53 blockade by the A(2A) adenosine receptor via a novel interacting protein, translin-associated protein X. *Mol Pharmacol*. 2006; 70:454–466. [PubMed: 16617164]
 38. Xu MH, Gong YS, Su MS, Dai ZY, Dai SS, Bao SZ, Li N, Zheng RY, He JC, Chen JF, Wang XT. Absence of the adenosine A2A receptor confers pulmonary arterial hypertension and increased pulmonary vascular remodeling in mice. *J Vasc Res*. 2011; 48:171–183. [PubMed: 20938208]
 39. Huang H, Zhang P, Wang Z, Tang F, Jiang Z. Activation of endothelin-1 receptor signaling pathways is associated with neointima formation, neoangiogenesis and irreversible pulmonary artery hypertension in patients with congenital heart disease. *Circ J*. 2011; 75:1463–1471. [PubMed: 21498912]

40. Moreno-Vinasco L, Gomberg-Maitland M, Maitland ML, Desai AA, Singleton PA, Sammani S, Sam L, Liu Y, Husain AN, Lang RM, Ratain MJ, Lussier YA, Garcia JG. Genomic assessment of a multikinase inhibitor, sorafenib, in a rodent model of pulmonary hypertension. *Physiol Genomics*. 2008; 33:278–291. [PubMed: 18303084]
41. Tu L, Dewachter L, Gore B, Fadel E, Darteville P, Simonneau G, Humbert M, Eddahibi S, Guignabert C. Autocrine fibroblast growth factor-2 signaling contributes to altered endothelial phenotype in pulmonary hypertension. *Am J Respir Cell Mol Biol*. 2011; 45:311–322. [PubMed: 21037114]
42. Adair TH. Growth regulation of the vascular system: an emerging role for adenosine. *Am J Physiol Regul Integr Comp Physiol*. 2005; 289:R283–R296. [PubMed: 16014444]
43. Aird WC. Endothelial cell heterogeneity. *Cold Spring Harb Perspect Med*. 2012; 2:a006429. [PubMed: 22315715]
44. Farber HW, Center DM, Rounds S. Effect of ambient oxygen on cultured endothelial cells from different vascular beds. *Am J Physiol*. 1987; 253:H878–883. [PubMed: 3661737]
45. Shahani T, Lavend'homme R, Luttun A, Saint-Remy JM, Peerlinck K, Jacquemin M. Activation of human endothelial cells from specific vascular beds induces the release of a FVIII storage pool. *Blood*. 2010; 115:4902–4909. [PubMed: 20351306]
46. Carini R, Grazia De Cesaris M, Splendore R, Baldanzi G, Nitti MP, Alchera E, Filigheddu N, Domenicotti C, Pronzato MA, Graziani A, Albano E. Role of phosphatidylinositol 3-kinase in the development of hepatocyte preconditioning. *Gastroenterology*. 2004; 127:914–923. [PubMed: 15362046]
47. Flajolet M, Wang Z, Futter M, Shen W, Nuangchamnon N, Bendor J, Wallach I, Nairn AC, Surmeier DJ, Greengard P. FGF acts as a co-transmitter through adenosine A(2A) receptor to regulate synaptic plasticity. *Nat Neurosci*. 2008; 11:1402–1409. [PubMed: 18953346]
48. Li HQ, Luo Y, Qiao CH. The mechanisms of anticancer agents by genistein and synthetic derivatives of isoflavone. *Mini Rev Med Chem*. 2012; 12:350–362. [PubMed: 22303948]
49. Matori H, Umar S, Nadadur RD, Sharma S, Partow-Navid R, Afkhami M, Amjadi M, Eghbali M. Genistein, a soy phytoestrogen, reverses severe pulmonary hypertension and prevents right heart failure in rats. *Hypertension*. 2012; 60:425–430. [PubMed: 22753213]

Highlights

A_{2A} receptor-induced pulmonary endothelial growth is mediated by PI3K and ERK1/2.

Cytosolic calcium mobilization is also critical for pulmonary endothelial growth.

Effectors of A_{2A} receptor, like tyrosine kinases and cAMP increase PI3K/Akt signaling.

Activation of A_{2A} receptor can contribute to vascular remodeling.

Figure 1. Adenosine A_{2A} receptor overexpression-induced HLMVEC proliferation is mediated by cytosolic calcium mobilization, ERK1/2 and PI3K

1.3×10^5 cells/well were cultured on 6-well plates. Cells were transduced with Ad.LacZ or Ad.A_{2A} in medium containing 2% FBS. Twenty-four hours post transduction diluent or inhibitors of ERK1/2 (U0126: 10 μ M), PI3K (LY294002: 10 μ M), calcium mobilization (BAPTA: 10 μ M), or A_{2A} receptor antagonist (SCH442416: 100 nm) were added and cells were counted after an additional 24 h. Panel A shows representative images of cells prior to harvest for cell counts. Panel B shows cell counts in the presence or absence of inhibitors. Values are expressed as mean $\pm$ SEM (n=4). *P<0.05 indicates significant difference from

non-transduced and Ad.LacZ control. #P<0.05 indicates significant difference from Ad.A_{2A} transduced cells.

Figure 2. Adenosine A_{2A} receptor activation mediates cytosolic calcium mobilization in HLMVECs

Cells were cultured on 96-well plates to 80% confluence and transduced. Forty eight hours later intracellular calcium mobilization upon buffer (control), ATP (positive control) or CGS21680 was assayed in cells preloaded with no wash (NW) Fluo-4 calcium sensing dye as described in the methods. The graph shows the mean peak values $\pm$ SEM (n=8). Inset shows the representative time-dependent calcium mobilization curves. *P<0.05 indicates significant difference from buffer control.

Figure 3. Effect of adenosine and CGS21680 on Akt phosphorylation and PI3K activity

(A) Cells were serum-starved for 48 h in EBM2 with 0.1% human serum albumin after which adenosine (100 μ M) or 2-Cl-Ado (1 μ M) was added. After a 10 min incubation, cell lysates were prepared and 500 μ g of protein was incubated with 20 μ l (200 μ g) of anti-p85-conjugated agarose, and the PI3K activity was measured in the immunoprecipitate as described in Methods. Upper panel shows a representative autoradiogram demonstrating PI3K-mediated phosphorylation of phosphoinositides. The lower panel shows a quantitative representation of PI3K activity as assessed by densitometry of the scans of spots obtained by autoradiogram. Results are arbitrary densitometric units. (B) Cells were similarly serum starved and treated with CGS21680 for 10 min after which PI3K activity was measured. (C) Cells were similarly serum starved and treated with adenosine (100 μ M) for 10 min after which western blotting was performed using phospho-Akt (Ser473) antibody. (D) Cells were similarly serum starved and treated with CGS21680 (1 μ M) for 10 min after which western blotting was performed using phospho-Akt (Ser473) antibody. Blots were subsequently stripped and probed with Akt antibody. (E) Serum-starved cells were treated with CGS21680 (1 μ M) for 10 min in the presence or absence of Genistein (1 μ M) after which lysates were made and western blotting was performed using phospho-Akt (Ser473) antibody. Blots were subsequently stripped and probed with Akt antibody. (F) Serum-starved cells were treated with the A_{2A} receptor agonist, CGS21680 (1 μ M). cAMP was measured using ELISA. (G) Similarly serum-starved cells were treated with 8-Br-cAMP, a stable analog of cAMP, and PI3K activity measured.

Figure 4. Adenosine A_{2A} receptor activation enhances ERK1/2 phosphorylation

(A) Cells were serum starved for 48 h in EBM2 with 0.1% human serum albumin after which CGS21680 (1 μ M) was added. After 10 min incubation, cell lysates were prepared and western blotting performed using phospho-ERK1/2 (Tyr 202/Thr 204) antibody. Blots were subsequently stripped and probed with ERK1/2 antibody. (B) Cells were transduced with Ad.A_{2A} or the control Ad.LacZ in complete EBM2 medium and serum starved for 24 h after which CGS21680 (1 μ M) was added for 10 min. Cell lysates were then prepared and western blotting performed using phospho-ERK1/2 (Tyr 202/Thr 204) antibody. Blots were subsequently stripped and probed with ERK1/2 antibody.